Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-Hodgkin's Lymphoma

Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (⩾60 years) with non-Hodgkin’s lymphoma: comparison with patients <60 years treated within the same protocol

Bone Marrow Transplantation volume 26, pages 737–741 (2000)Cite this article

Abstract

Limited data are available concerning feasibility and toxicity of progenitor cell mobilization and high-dose therapy (HDT) supported by peripheral blood stem cell transplantation (PBSCT) in elderly patients (⩾60 years) with non-Hodgkin’s lymphoma (NHL). From 1995 to 1999, 17 elderly NHL patients (median age 63 years, range 60–70) entered our HDT program and were mobilized with CY (4 g/m2) followed by G-CSF. Mobilization was successful in 13 patients, who then received BEAM or BEAC followed by PBSCT. The feasibility and toxicity of progenitor cell mobilization and HDT in the elderly patients were compared with experiences in 62 NHL patients <60 years (median 46 years, range 16–59), who received the same mobilization protocol and of whom 48 patients received hdt supported by pbsct. no significant differences were observed between these groups in the success rate of progenitor cell mobilization, in the number of cd34-positive cells collected or in the number of aphereses needed. hdt appeared to be somewhat more toxic in the elderly patients: a higher peak crp value (P = 0.08) and longer in-hospital stay (P = 0.05) were observed. no differences were found in transplant-related mortality or severe organ toxicity between these age groups except for oral mucositis grade >2, which tended to be more common in the elderly patients (P = 0.07). We conclude that progenitor cell mobilization and HDT supported by PBSCT is also feasible in selected elderly patients with NHL. Bone Marrow Transplantation (2000) 26, 737–741.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin’s lymphoma New Engl J Med 1995 333: 1540–1545

    Article  CAS  PubMed  Google Scholar 

  2. Verdonck LF, van Putten WLJ, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma New Engl J Med 1995 332: 1045–1051

    Article  CAS  PubMed  Google Scholar 

  3. Martelli M, Vignetti M, Zinzani PL et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin’s lymphoma with partial response to front line chemotherapy: a prospective randomized Italian multicenter trial J Clin Oncol 1996 14: 534–542

    Article  CAS  PubMed  Google Scholar 

  4. Pettengell R, Radford JA, Morgenstern GR et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin’s lymphoma J Clin Oncol 1996 14: 586–592

    Article  CAS  PubMed  Google Scholar 

  5. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH 87-2 J Clin Oncol 1997 15: 1131–1137

    Article  CAS  PubMed  Google Scholar 

  6. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma New Engl J Med 1997 336: 1290–1297

    Article  CAS  PubMed  Google Scholar 

  7. Sweetenham JW, Pearce R, Philip T et al. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin’s lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation Bone Marrow Transplant 1994 14: 981–987

    CAS  PubMed  Google Scholar 

  8. Miller CB, Piantadosi S, Vogelsang GB et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant J Clin Oncol 1996 14: 1327–1332

    Article  CAS  PubMed  Google Scholar 

  9. Kusnierz-Glaz CR, Schlegel PG, Wong RM et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies J Clin Oncol 1997 15: 18–25

    Article  CAS  PubMed  Google Scholar 

  10. Goss PR . Non-Hodgkin’s lymphoma in elderly patients Leuk Lymphoma 1993 10: 147–156

    Article  CAS  PubMed  Google Scholar 

  11. Dixon DO, Neilan B, Jones SE et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma J Clin Oncol 1986 4: 295–305

    Article  CAS  PubMed  Google Scholar 

  12. Vose JM, Armitage JO, Weisenburger DD et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma J Clin Oncol 1988 6: 1838–1844

    Article  CAS  PubMed  Google Scholar 

  13. Shipp MA, Harrington DP, Anderson JR et al. The International non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma New Engl J Med 1993 329: 987–994

    Article  Google Scholar 

  14. Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment Cancer 1981 47: 207–214

    Article  CAS  PubMed  Google Scholar 

  15. Guba SC, Vesole DH, Jagannath S et al. Peripheral stem cell mobilization and engraftment in patients over age 60 Bone Marrow Transplant 1997 20: 1–3

    Article  CAS  PubMed  Google Scholar 

  16. Stamatoullas A, Fruchart C, Khalfallah S et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age Bone Marrow Transplant 1997 19: 31–35

    Article  CAS  PubMed  Google Scholar 

  17. Moreau P, Milpied N, Voillat L et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61–65 years: a pilot study Bone Marrow Transplant 1998 21: 1193–1196

    Article  CAS  PubMed  Google Scholar 

  18. Mazza F, Palazzo G, Amurri A et al. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report Bone Marrow Transplant 1999 23: 1273–1278

    Article  CAS  PubMed  Google Scholar 

  19. Millar JL, McElwain TJ, Clutterbuck RD, Wist EA . The modification of melphalan toxicity in tumor bearing mice by S-2(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721) Am J Clin Oncol 1982 5: 321–328

    Article  CAS  PubMed  Google Scholar 

  20. Ketterer N, Salles G, Raba M et al. High CD34+ counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation Blood 1998 91: 3148–3156

    CAS  PubMed  Google Scholar 

  21. Karthaus M, Rosenthal C, Ganser A . Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis—are there new strategies? Bone Marrow Transplant 1999 24: 1095–1108

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Kuopio University Hospital, Kuopio, Finland

    E Jantunen & T Nousiainen

  2. Department of Clinical Chemistry, Kuopio University Hospital, Kuopio, Finland

    E Mahlamäki

Authors
  1. E Jantunen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Mahlamäki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Nousiainen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jantunen, E., Mahlamäki, E. & Nousiainen, T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (⩾60 years) with non-Hodgkin’s lymphoma: comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant 26, 737–741 (2000). https://doi.org/10.1038/sj.bmt.1702577

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702577

Keywords

This article is cited by

Search

Advanced search

Quick links